Financial Performance - The total revenue for the year ended December 31, 2022, was RMB 1,201,604,254.24, representing an increase of 8.4% compared to RMB 1,108,139,520.61 in 2021[6] - The operating profit for 2022 was RMB 328,908,764.68, a decrease of 10.5% from RMB 367,591,655.59 in the previous year[6] - The net profit attributable to shareholders for 2022 was RMB 1,136,732,358.10, up from RMB 908,847,424.37 in 2021, marking a growth of 25.1%[5] - The total profit for the year ended December 31, 2022, was RMB 336,879,766.43, a decrease of 8.3% from RMB 367,378,723.41 in 2021[7] - The net profit attributable to the parent company's shareholders for 2022 was RMB 307,719,145.65, down 4.0% from RMB 322,360,736.79 in 2021[9] - Basic earnings per share for 2022 were RMB 0.80, compared to RMB 0.93 in 2021, reflecting a decline of 14.0%[10] - The income tax expense for 2022 was RMB 29,160,620.78, significantly lower than RMB 45,017,986.62 in 2021, indicating a reduction of 35.3%[7] - The total comprehensive income attributable to the parent company's shareholders for 2022 was RMB 307,719,145.65, compared to RMB 322,360,736.79 in 2021, showing a decrease of 4.0%[10] Assets and Liabilities - The total assets as of December 31, 2022, amounted to RMB 3,409,766,690.91, compared to RMB 2,999,657,361.45 in 2021, indicating a growth of 13.7%[2] - The total liabilities as of December 31, 2022, were RMB 690,066,911.19, an increase from RMB 530,579,974.97 in 2021[4] - The total equity attributable to shareholders increased to RMB 2,719,699,779.72 in 2022 from RMB 2,469,077,386.48 in 2021, representing a growth of 10.1%[5] - The cash and cash equivalents as of December 31, 2022, were RMB 957,193,661.02, compared to RMB 767,727,534.25 in 2021, reflecting an increase of 24.7%[2] - As of December 31, 2022, the accounts receivable amounted to RMB 540,695,593.77, with a provision for bad debts of RMB 51,949,099.75, representing 9.61% of the total[14] - The total accounts payable as of December 31, 2022, was RMB 237,786,563.39, an increase of 67.0% from RMB 142,415,529.82 in 2021[3] Research and Development - Research and development expenses increased to RMB 162,340,798.73 in 2022, up from RMB 104,843,140.53 in 2021, reflecting a growth of 55%[6] - The company plans to continue investing in R&D to enhance product offerings and expand market presence in the coming years[6] - The company emphasizes R&D with a team of professionals, including PhDs and experienced personnel, ensuring continuous product innovation[36] - The company collaborates with clinical experts to ensure that its R&D products meet market demands and clinical practicality[36] - The company has initiated a large-scale clinical follow-up project involving over 300 hospitals in China, focusing on joint prosthetics[36] - The company obtained 21 testing qualifications by December 31, 2022, and its laboratory will undertake significant R&D projects for the nation, enhancing the safety and scientific design of new products[37] - The company led the application for a key national R&D project in 2020, focusing on the development and clinical application of multi-channel tantalum bone repair materials, which was approved by the Ministry of Science and Technology of the People's Republic of China[37] Market and Product Development - The orthopedic implant market in China is expected to grow due to factors such as an aging population, increasing medical expenditures, and improvements in public healthcare infrastructure[29] - The company has obtained 16 product registration certificates from the National Medical Products Administration in 2022, enhancing its product line and expanding its presence in the orthopedic field[31] - The company entered the oral field with registration certificates for orthodontic brackets, buccal tubes, and maxillofacial osteosynthesis systems, marking its official entry into this sector[33] - The company is developing an advanced customized joint prosthetic product using 3D reconstruction technology, targeting a broader range of patients and expected to yield higher profit margins[63] - The company anticipates continued growth in demand for its products, aligning with the expansion of the Chinese joint prosthetic market[62] - The company is focusing on the development of spinal products and sports medicine products alongside its joint prosthetic offerings[64] Corporate Governance and Shareholder Information - The company has adhered to all applicable principles and provisions of the corporate governance code as of December 31, 2022[75] - The board of directors proposed a final dividend of RMB 3.13 per 10 shares for the fiscal year ending December 31, 2022, compared to RMB 1.30 per 10 shares for the previous year[69] - The company will hold its annual general meeting on June 28, 2023, for shareholders to approve the proposed final dividend[70] - The company successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 30, 2021, raising a total of RMB 1,145,538,680.00, netting RMB 1,067,128,292.23 after expenses[73] Employee and Talent Management - The company employed a total of approximately 1,303 employees as of December 31, 2022, with total salary and related costs amounting to approximately RMB 193.41 million[67] - The company has established an effective incentive mechanism to motivate employees and attract high-quality talent through a competitive compensation system[66] - The company will recruit more R&D talent and enhance collaboration with renowned medical institutions to strengthen its professional knowledge and competitiveness[64]
春立医疗(01858) - 2022 - 年度业绩